These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 22355357)

  • 1. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
    Zito CR; Jilaveanu LB; Anagnostou V; Rimm D; Bepler G; Maira SM; Hackl W; Camp R; Kluger HM; Chao HH
    PLoS One; 2012; 7(2):e31331. PubMed ID: 22355357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.
    Aziz SA; Jilaveanu LB; Zito C; Camp RL; Rimm DL; Conrad P; Kluger HM
    Clin Cancer Res; 2010 Dec; 16(24):6029-39. PubMed ID: 21169255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer.
    Elfiky AA; Aziz SA; Conrad PJ; Siddiqui S; Hackl W; Maira M; Robert CL; Kluger HM
    J Transl Med; 2011 Aug; 9():133. PubMed ID: 21834980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
    J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels of p27 sensitize to dual PI3K/mTOR inhibition.
    Lee M; Theodoropoulou M; Graw J; Roncaroli F; Zatelli MC; Pellegata NS
    Mol Cancer Ther; 2011 Aug; 10(8):1450-9. PubMed ID: 21646547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
    Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin.
    Khan N; Afaq F; Khusro FH; Mustafa Adhami V; Suh Y; Mukhtar H
    Int J Cancer; 2012 Apr; 130(7):1695-705. PubMed ID: 21618507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
    Santiskulvong C; Konecny GE; Fekete M; Chen KY; Karam A; Mulholland D; Eng C; Wu H; Song M; Dorigo O
    Clin Cancer Res; 2011 Apr; 17(8):2373-84. PubMed ID: 21372221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J
    Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
    Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
    J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
    Gallagher EJ; Fierz Y; Vijayakumar A; Haddad N; Yakar S; LeRoith D
    Oncogene; 2012 Jul; 31(27):3213-22. PubMed ID: 22037215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
    O'Brien NA; McDonald K; Tong L; von Euw E; Kalous O; Conklin D; Hurvitz SA; di Tomaso E; Schnell C; Linnartz R; Finn RS; Hirawat S; Slamon DJ
    Clin Cancer Res; 2014 Jul; 20(13):3507-20. PubMed ID: 24879796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
    Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
    Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
    Sun Z; Wang Z; Liu X; Wang D
    Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
    Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y
    PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
    Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
    Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
    Chen MH; Chiang KC; Cheng CT; Huang SC; Chen YY; Chen TW; Yeh TS; Jan YY; Wang HM; Weng JJ; Chang PM; Liu CY; Li CP; Chao Y; Chen MH; Huang CY; Yeh CN
    Oncotarget; 2014 May; 5(9):2372-89. PubMed ID: 24796583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.